Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [NCI-H660]

ABSTRACT: ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [NCI-H660]

PROVIDER: PRJNA922169 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23025113_1.fastq.gz	Fastqsanger.gz
	SRR23025113_2.fastq.gz	Fastqsanger.gz
	SRR23025114_1.fastq.gz	Fastqsanger.gz
	SRR23025114_2.fastq.gz	Fastqsanger.gz
	SRR23025115_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [NCI-H660]

Project description:Here we demonstrated that the RNA-binding protein ELAVL3 is specifically upregulated in NEPC, and that overexpression of ELAVL3 alone sufficiently induce neuroendocrine phenotype in prostate adenocarcinoma. Pharmacological inhibition of ELAVL3 with pyrvinium pamoate, an FDA-approved drug, effectively suppressed tumor growth, reduced the risk of metastases, and improved the survival of NEPC mice models.

2023-10-23 | GSE222469 | GEO